ACER-001 Study Initiated for MCADD in Pediatric and Adult Patients
A clinical trial is underway to evaluate sodium phenylbutyrate (ACER-001) for treating MCADD in patients aged 4 and older.
Phase III
Metabolic Disorders / Medium Chain Acyl-CoA Dehydrogenase Deficiency
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the ACER-001 study for MCADD is significant as it could lead to an expanded indication for a drug currently approved for Urea Cycle Disorders. Success in this trial may enhance competitive positioning and market share within the metabolic disorders therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and safety data as they become available, particularly regarding efficacy in MCADD.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.